Yiqiao Xin
Education
Ph.D., health economics, University of Glasgow; M.Sc., health technology assessment and management, Université de Montréal; B.Sc., pharmacy, China Pharmaceutical University
Summary of Experience
Dr. Xin specializes in health economics and outcomes research (HEOR). She provides expertise in decision-analytic modeling methods for health technology appraisals (HTA) and has led the design and implementation of cost-effectiveness and budget impact models in multiple countries. Dr. Xin’s work has also involved evidence synthesis such as network meta-analyses and matching-adjusted indirect comparisons, indirect treatment comparisons with individual-level patient data, clinical trial analyses, survey development, and patient-reported outcome (PRO) studies. Her work spans a broad range of disease areas, including oncology, immunology, dermatology, cardiovascular diseases, diabetes, and neurology. Prior to joining Analysis Group, Dr. Xin was a research associate at an academic institution, where she focused on trial- and model-based economic evaluations and PROs, as well as providing expertise on complex literature reviews and developing R Shiny applications for conducting network meta-analysis. Her work has been presented at clinical and economic research conferences and published in various peer-reviewed journals.
-
First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data
Journal of Clinical Oncology, 2024
2024Long GV, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao C; Grob JJ, Ejzykowicz F, Moshyk A, Garcia-Horton V, Zhou ZY, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Patel D, Sakkal LA, Tawbi H, Schadendorf D
-
Association between event-free survival and overall survival in early-stage triple-negative breast cancer
Future Oncology, 2023
2023Huang M, Fasching PA, Haiderali A, Xue W, Pan W, Karantza V, Yang F, Truscott J, Xin Y, O'Shaughnessy J